The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Current Challenges and Opportunities in Treating Glioblastoma
Open accessAbstract
that are overexpressed in a subpopulation of GBM patients and correlate with poor survival outcomes. Importantly, nine of these genes exhibit higher expression in GBM versus low-grade glioma and may be involved in disease progression. In this review, we discuss these proteins in the context of GBM disease progression. We also conducted computational multi-parameter optimization to assess the blood-brain barrier (BBB) permeability of small molecules in clinical trials for GBM treatment. Drug delivery in the context of GBM is particularly challenging because the BBB hinders small molecule transport. Therefore, we discuss novel drug delivery methods, including nanoparticles and prodrugs. Given the aggressive nature of GBM and the complexity of targeting the central nervous system, effective treatment options are a major unmet medical need. Identification and validation of biomarkers and drug targets associated with GBM disease progression present an exciting opportunity to improve treatment of this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ranković, Z. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01469 · Cited by 97
RetractedR: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Substituent constants for correlation analysis in chemistry and biology
Hansch, C. H., & Leo, A. J. (1979) · Medical Entomology and Zoology · Cited by 2,903
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Maier-Hauff, K., Ulrich, F., Nestler, D., Niehoff, H., Wust, P., Thiesen, B., Orawa, H., Budach, V., & Jordan, A. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0389-0 · Cited by 1,429
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Ostrom, Q. T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now207 · Cited by 1,204
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Role of amino acid transport and countertransport in nutrition and metabolism.
Christensen, H. N. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.1.43 · Cited by 1,099
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
Mandriota, S. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.672 · Cited by 978
Xue, J., Zhao, Z., Zhang, L., Xue, L., Shen, S., Wen, Y., Wei, Z., Wang, L., Kong, L., Sun, H., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.54 · Cited by 959
Recent Progress in Cancer Thermal Therapy Using Gold Nanoparticles
Abadeer, N. S., & Murphy, C. J. (2016) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.5b11232 · Cited by 919
Taal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 759
Gene Expression Profiling of Gliomas Strongly Predicts Survival
Freije, W. A., Castro-Vargas, F. E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L. M., Mischel, P. S., & Nelson, S. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0452 · Cited by 744
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of Drug Targeting · doi:10.1080/10611860400015936 · Cited by 742
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis
Gupta, G. P., Nguyen, D. X., Chiang, A. C., Bos, P. D., Kim, J. Y., Nadal, C., Gomis, R. R., Manova-Todorova, K., & Massagué, J. (2007) · Nature · doi:10.1038/nature05760 · Cited by 727
Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 721
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Patient-derived xenografts undergo mouse-specific tumor evolution
Ben-David, U., Ha, G., Tseng, Y.-Y., Greenwald, N. F., Oh, C., Shih, J., McFarland, J. M., Wong, B., Boehm, J. S., Beroukhim, R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3967 · Cited by 716
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
Phillips, E., Penate-Medina, O., Zanzonico, P. B., Carvajal, R. D., Mohan, P., Ye, Y., Humm, J., Gönen, M., Kalaigian, H., Schöder, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009524 · Cited by 712
Lang, F. F., Conrad, C., Gomez-Manzano, C., Yung, W. K. A., Sawaya, R., Weinberg, J. S., Prabhu, S. S., Rao, G., Fuller, G. N., Aldape, K. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.8219 · Cited by 711
Characteristics of Compounds that Cross the Blood-Brain Barrier
Banks, W. A. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s3 · Cited by 710
Alcantara Llaguno, S., Chen, J., Kwon, C.-H., Jackson, E. L., Li, Y., Burns, D. K., Alvarez-Buylla, A., & Parada, L. F. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.006 · Cited by 694
Roles for Nkx3.1 in prostate development and cancer
Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M., Desai, N., Young, P., Norton, C. R., Gridley, T., Cardiff, R. D., Cunha, G. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.8.966 · Cited by 665
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L., & Leitman, D. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2446 · Cited by 576
The “On–Off” Phenomenon in Parkinson’s Disease: Relation to Levodopa Absorption and Transport
Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., & Anderson, J. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402233100802 · Cited by 554
Biological Functions of the Small Leucine-rich Proteoglycans: From Genetics to Signal Transduction
Schaefer, L., & Iozzo, R. V. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800020200 · Cited by 549
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Wiley, D. T., Webster, P., Gale, A., & Davis, M. E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307152110 · Cited by 519
Junctional adhesion molecules (JAMs): more molecules with dual functions?
Ebnet, K., Suzuki, A., Ohno, S., & Vestweber, D. (2004) · Journal of Cell Science · doi:10.1242/jcs.00930 · Cited by 501
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Advanced drug delivery systems: Nanotechnology of health design A review
Safari, J., & Zarnegar, Z. (2014) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2012.12.009 · Cited by 429
Liu, Y.-C., Yen, H.-Y., Chen, C.-Y., Chen, C.-H., Cheng, P.-F., Juan, Y.-H., Chen, C.-H., Khoo, K.-H., Yu, C.-J., Yang, P.-C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107385108 · Cited by 424
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
The Hedgehog Signal Transduction Network
Robbins, D. J., Fei, D. L., & Riobo, N. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002906 · Cited by 419
Substituent constants for correlation analysis
Hansch, C., Rockwell, S. D., Jow, P. Y. C., Leo, A., & Steller, E. E. (1977) · Journal of Medicinal Chemistry · doi:10.1021/jm00212a024 · Cited by 416
Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.
Friden, P. M., Walus, L. R., Musso, G. F., Taylor, M. A., Malfroy, B., & Starzyk, R. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4771 · Cited by 402
Granzymes in cancer and immunity
Cullen, S. P., Brunet, M., & Martin, S. J. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.206 · Cited by 391
Tenzen, T., Allen, B. L., Cole, F., Kang, J.-S., Krauss, R. S., & McMahon, A. P. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.04.004 · Cited by 389
EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics
Freed, D. M., Bessman, N. J., Kiyatkin, A., Salazar-Cavazos, E., Byrne, P. O., Moore, J. O., Valley, C. C., Ferguson, K. M., Leahy, D. J., Lidke, D. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.017 · Cited by 383
Macromolecular permeability across the blood-nerve and blood-brain barriers.
Poduslo, J. F., Curran, G. L., & Berg, C. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5705 · Cited by 377
Cancer-Related Axonogenesis and Neurogenesis in Prostate Cancer
Ayala, G. E., Dai, H., Powell, M., Li, R., Ding, Y., Wheeler, T. M., Shine, D., Kadmon, D., Thompson, T., Miles, B. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1164 · Cited by 377
Jacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.-L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3744 · Cited by 368
Oncogenic EGFR Signaling Networks in Glioma
Huang, P. H., Xu, A. M., & White, F. M. (2009) · Science Signaling · doi:10.1126/scisignal.287re6 · Cited by 363
Blood-Brain Barrier: Penetration of Morphine, Codeine, Heroin, and Methadone after Carotid Injection
Oldendorf, W. H., Hyman, S., Braun, L., & Oldendorf, S. Z. (1972) · Science · doi:10.1126/science.178.4064.984 · Cited by 362
He, W. W., Sciavolino, P. J., Wing, J., Augustus, M., Hudson, P., Meissner, P. S., Curtis, R. T., Shell, B. K., Bostwick, D. G., Tindall, D. J., et al. (1997) · Genomics · doi:10.1006/geno.1997.4715 · Cited by 361
Blood-brain barrier transcytosis of insulin in developing rabbits
Duffy, K. R., & Pardridge, W. M. (1987) · Brain Research · doi:10.1016/0006-8993(87)90236-8 · Cited by 358
Medema, J. P., de Jong, J., Peltenburg, L. T. C., Verdegaal, E. M. E., Gorter, A., Bres, S. A., Franken, K. L. M. C., Hahne, M., Albar, J. P., Melief, C. J. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201398198 · Cited by 356
Multifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 349
Cheng, S. Y., Huang, H. J., Nagane, M., Ji, X. D., Wang, D., Shih, C. C., Arap, W., Huang, C. M., & Cavenee, W. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8502 · Cited by 342
Xie, Y., Bergström, T., Jiang, Y., Johansson, P., Marinescu, V. D., Lindberg, N., Segerman, A., Wicher, G., Niklasson, M., Baskaran, S., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.026 · Cited by 333
Gene expression profiling and genetic markers in glioblastoma survival
Rich, J. N., Hans, C., Jones, B., Iversen, E. S., McLendon, R. E., Rasheed, B. K. A., Dobra, A., Dressman, H. K., Bigner, D. D., Nevins, J. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3936 · Cited by 316
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
Petri, B., Bootz, A., Khalansky, A., Hekmatara, T., Müller, R., Uhl, R., Kreuter, J., & Gelperina, S. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.015 · Cited by 298
Vorbrodt, A. W., & Dobrogowska, D. H. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00177-2 · Cited by 293
Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
Bhowmik, A., Khan, R., & Ghosh, M. K. (2015) · BioMed Research International · doi:10.1155/2015/320941 · Cited by 291
One mouse, one patient paradigm: New avatars of personalized cancer therapy
Malaney, P., Nicosia, S. V., & Davé, V. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.010 · Cited by 289
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling
Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C. B., Zapatka, M., Northcott, P. A., Schramm, K., Belic, J., Jones, D. T. W., Tschida, B., Moriarity, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8391 · Cited by 283
In vivo models of primary brain tumors: pitfalls and perspectives
Huszthy, P. C., Daphu, I., Niclou, S. P., Stieber, D., Nigro, J. M., Sakariassen, P. O., Miletic, H., Thorsen, F., & Bjerkvig, R. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos135 · Cited by 282
Pharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279
O'Reilly, S. M., Newlands, E. S., Brampton, M., Glaser, M. G., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Kennard, C., Colquhoun, I. R., Lewis, P., et al. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80198-4 · Cited by 277
Ultrasound treatment of neurological diseases — current and emerging applications
Leinenga, G., Langton, C., Nisbet, R., & Götz, J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.13 · Cited by 275
Gaillard, P. J., Appeldoorn, C. C. M., Dorland, R., van Kregten, J., Manca, F., Vugts, D. J., Windhorst, B., van Dongen, G. A. M. S., de Vries, H. E., Maussang, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082331 · Cited by 273
Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer
Chen, C.-Y., Jan, Y.-H., Juan, Y.-H., Yang, C.-J., Huang, M.-S., Yu, C.-J., Yang, P.-C., Hsiao, M., Hsu, T.-L., & Wong, C.-H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220425110 · Cited by 266
Ishida, O., Maruyama, K., Tanahashi, H., Iwatsuru, M., Sasaki, K., Eriguchi, M., & Yanagie, H. (2001) · Pharmaceutical Research · doi:10.1023/a:1010960900254 · Cited by 257
Agarwal, S., Sane, R., Gallardo, J. L., Ohlfest, J. R., & Elmquist, W. F. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167601 · Cited by 255
Non-Stem Cell Origin for Oligodendroglioma
Persson, A. I., Petritsch, C., Swartling, F. J., Itsara, M., Sim, F. J., Auvergne, R., Goldenberg, D. D., Vandenberg, S. R., Nguyen, K. N., Yakovenko, S., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.033 · Cited by 242
Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases.
Abate-Shen, C. T., Banach-Petrosky, W. A., Sun, X., et al. (2003) · PubMed · Cited by 228
IKKα, IKKβ, and NEMO/IKKγ Are Each Required for the NF-κB-mediated Inflammatory Response Program
Li, X., Massa, P. E., Hanidu, A., Peet, G. W., Aro, P., Savitt, A., Mische, S., Li, J., & Marcu, K. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205165200 · Cited by 223
Capparuccia, L., & Tamagnone, L. (2009) · Journal of Cell Science · doi:10.1242/jcs.030197 · Cited by 206
Temozolomide Nanoparticles for Targeted Glioblastoma Therapy
Fang, C., Wang, K., Stephen, Z. R., Mu, Q., Kievit, F. M., Chiu, D. T., Press, O. W., & Zhang, M. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am5092165 · Cited by 204
Zhu, J.-X., Goldoni, S., Bix, G., Owens, R. T., McQuillan, D. J., Reed, C. C., & Iozzo, R. V. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503833200 · Cited by 201
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma
Miller, T. E., Liau, B. B., Wallace, L. C., Morton, A. R., Xie, Q., Dixit, D., Factor, D. C., Kim, L. J. Y., Morrow, J. J., Wu, Q., et al. (2017) · Nature · doi:10.1038/nature23000 · Cited by 200
Granzyme B-induced apoptosis in cancer cells and its regulation (Review)
Krepela (2010) · International Journal of Oncology · doi:10.3892/ijo_00000788 · Cited by 194
Transport of nanoparticles through the blood–brain barrier for imaging and therapeutic applications
Shilo, M., Motiei, M., Hana, P., & Popovtzer, R. (2014) · Nanoscale · doi:10.1039/c3nr04878k · Cited by 193
Epiregulin: Roles in normal physiology and cancer
Riese, D. J., & Cullum, R. L. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.03.005 · Cited by 192
Edwards, D. K., Jasny, E., Yoon, H., Horscroft, N., Schanen, B., Geter, T., Fotin-Mleczek, M., Petsch, B., & Wittman, V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1111-6 · Cited by 186
Gorlia, T., Stupp, R., Brandes, A. A., Rampling, R. R., Fumoleau, P., Dittrich, C., Campone, M. M., Twelves, C. C., Raymond, E., Hegi, M. E., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.004 · Cited by 186
Development of orally active inhibitors of protein and cellular fucosylation
Okeley, N. M., Alley, S. C., Anderson, M. E., Boursalian, T. E., Burke, P. J., Emmerton, K. M., Jeffrey, S. C., Klussman, K., Law, C.-L., Sussman, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222263110 · Cited by 184
Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion
Jahrsdörfer, B., Vollmer, A., Blackwell, S. E., Maier, J., Sontheimer, K., Beyer, T., Mandel, B., Lunov, O., Tron, K., Nienhaus, G. U., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235382 · Cited by 180
Seidler, D. G., Goldoni, S., Agnew, C., Cardi, C., Thakur, M. L., Owens, R. T., McQuillan, D. J., & Iozzo, R. V. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602853200 · Cited by 180
The blood-brain barrier and oncology: new insights into function and modulation
Bart, J., Groen, H. J. M., Hendrikse, N. H., van der Graaf, W. T. A., Vaalburg, W., & de Vries, E. G. E. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0194 · Cited by 179
Prodrug Approaches for CNS Delivery
Rautio, J., Laine, K., Gynther, M., & Savolainen, J. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9009-8 · Cited by 176
Elovl6: a new player in fatty acid metabolism and insulin sensitivity
Matsuzaka, T., & Shimano, H. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0449-0 · Cited by 176
Wen, P. Y., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not247 · Cited by 171
Moos, T., & Morgan, E. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00541.x · Cited by 169
miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients
Akers, J. C., Ramakrishnan, V., Kim, R., Phillips, S., Kaimal, V., Mao, Y. Q., Hua, W., Yang, I., Fu, C.-C., Nolan, J. P., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1784-3 · Cited by 165
Hajjar, K. A., & Krishnan, S. (1999) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(99)00020-1 · Cited by 164
Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis
Iwadate, Y., Sakaida, T., Hiwasa, T., Nagai, Y., Ishikura, H., Takiguchi, M., & Yamaura, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1254 · Cited by 164
Enzyme-mediated hydrolytic activation of prodrugs
Yang, Y.-H., Aloysius, H., Inoyama, D., Chen, Y., & Hu, L.-Q. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.08.001 · Cited by 162
Two decades of new drug development for central nervous system disorders
Kesselheim, A. S., Hwang, T. J., & Franklin, J. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4793 · Cited by 160
Mo, J., He, L., Ma, B., & Chen, T. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b11730 · Cited by 159
de Vries, N. A., Buckle, T., Zhao, J., Beijnen, J. H., Schellens, J. H. M., & van Tellingen, O. (2012) · Investigational New Drugs · doi:10.1007/s10637-010-9569-1 · Cited by 158
Kim, S. S., Rait, A. S., Kim, E. H., Pirollo, K. F., Nishida, M., Farkas, N., Dagata, J. A., & Chang, E. H. (2014) · ACS Nano · doi:10.1021/nn5014484 · Cited by 158
Ayllón, V., & O’Connor, R. (2006) · Oncogene · doi:10.1038/sj.onc.1210142 · Cited by 157
Cloughesy, T. F., Finocchiaro, G., Belda-Iniesta, C., Recht, L. D., Brandes, A. A., Pineda, E., Mikkelsen, T., Chinot, O. L., Balañá, C., Macdonald, D. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.7685 · Cited by 150
Laksitorini, M. D., Prasasty, V. D., Kiptoo, P. K., & Siahaan, T. J. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.67 · Cited by 149
The proprotein convertase furin in tumour progression
Jaaks, P., & Bernasconi, M. (2017) · International Journal of Cancer · doi:10.1002/ijc.30714 · Cited by 148
Kang, T., Jiang, M., Jiang, D., Feng, X., Yao, J., Song, Q., Chen, H., Gao, X., & Chen, J. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00222 · Cited by 144
HMMR Maintains the Stemness and Tumorigenicity of Glioblastoma Stem-like Cells
Tilghman, J. I., Wu, H., Sang, Y., Shi, X., Guerrero‐Cazares, H., Quiñones‐Hinojosa, A., Eberhart, C. G., Laterra, J., & Ying, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2103 · Cited by 142
ErbB-2 and Met Reciprocally Regulate Cellular Signaling via Plexin-B1
Swiercz, J. M., Worzfeld, T., & Offermanns, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706822200 · Cited by 139
Active Transport of Fentanyl by the Blood-Brain Barrier
Henthorn, T. K., Liu, Y., Mahapatro, M., & Ng, K. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38239-4 · Cited by 135
Reardon, D. A., Groves, M. D., Wen, P. Y., Nabors, B., Mikkelsen, T., Rosenfeld, S., Raizer, J. J., Barriuso, J., McLendon, R. E., Suttle, A. B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1707 · Cited by 132
Cheng, Y., Meyers, J. D., Agnes, R. S., Doane, T. L., Kenney, M. E., Broome, A., Burda, C., & Basilion, J. P. (2011) · Small · doi:10.1002/smll.201100628 · Cited by 130
Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma
Lal, S., Verma, J., & Noorden, C. J. F. V. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s57501 · Cited by 129
Complex molecular regulation of tyrosine hydroxylase
Tekin, I., Roskoski, R., Carkaci-Salli, N., & Vrana, K. E. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1238-7 · Cited by 128
Song, H., Zhang, B., Watson, M. A., Humphrey, P. A., Lim, H. J., & Milbrandt, J. (2009) · Oncogene · doi:10.1038/onc.2009.181 · Cited by 123
Clinical trial end points for high-grade glioma: the evolving landscape
Reardon, D. A., Galanis, E., DeGroot, J. F., Cloughesy, T. F., Wefel, J. S., Lamborn, K. R., Lassman, A. B., Gilbert, M. R., Sampson, J. H., Wick, W., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq203 · Cited by 123
Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells
Gan, H. K., van den Bent, M. J., Lassman, A. B., Reardon, D. A., & Scott, A. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.95 · Cited by 122
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Karpel‐Massler, G., Ishida, C. T., Bianchetti, E., Zhang, Y., Shu, C., Tsujiuchi, T., Banu, M. A., Garcia, F., Roth, K. A., Bruce, J. N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00984-9 · Cited by 121
Current trends in mouse models of glioblastoma
Miyai, M., Tomita, H., Soeda, A., Yano, H., Iwama, T., & Hara, A. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2626-2 · Cited by 118
Transforming Properties of 8p11-12 Amplified Genes in Human Breast Cancer
Yang, Z.-Q., Liu, G., Bollig-Fischer, A. B., Giroux, C. N., & Ethier, S. P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1013 · Cited by 117
Granzymes and perforin in solid organ transplant rejection
Choy, J. C. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.161 · Cited by 116
Camp, E. R., Wang, C., Little, E. C., Watson, P. M., Pirollo, K. F., Rait, A. S., Cole, D. J., Chang, E. H., & Watson, D. K. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.9 · Cited by 115
Varnum, S. M., Covington, C. Y., Woodbury, R. L., Pétritis, K., Kangas, L. J., Abdullah, M. S., Pounds, J. G., Smith, R. D., & Zangar, R. C. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024479106887 · Cited by 115
Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets
Ordway, J. M., Bedell, J. A., Citek, R. W., Nunberg, A. N., Garrido, A., Kendall, R., Stevens, J. R., Cao, D., Doerge, R. W., Korshunova, Y. O., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl161 · Cited by 115
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
Heffron, T. P., Ndubaku, C. O., Salphati, L., Alicke, B., Cheong, J., Drobnick, J., Edgar, K. A., Gould, S. E., Lee, L. B., Lesnick, J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00005 · Cited by 113
Rindopepimut: A Promising Immunotherapeutic for the Treatment of Glioblastoma Multiforme
Swartz, A. M., Li, Q.-J., & Sampson, J. H. (2014) · Immunotherapy · doi:10.2217/imt.14.21 · Cited by 111
Dufies, M., Giuliano, S., Ambrosetti, D., Claren, A., Ndiaye, P. D., Mastri, M., Moghrabi, W. N., Cooley, L. S., Ettaiche, M., Chamorey, E., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3088 · Cited by 111
Stangeland, B., Mughal, A. A., Grieg, Z., Sandberg, C. J., Joel, M., Nygård, S., Meling, T. R., Murrell, W. G., Vik-Mo, E. O., & Langmoen, I. A. (2015) · Oncotarget · doi:10.18632/oncotarget.4613 · Cited by 110
Toyo‐oka, K., Sasaki, S., Yano, Y., Mori, D., Kobayashi, T., Toyoshima, Y. Y., Tokuoka, S. M., Ishii, S., Shimizu, T., Muramatsu, M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi339 · Cited by 106
Chacko, A., Li, C., Pryma, D. A., Brem, S. S., Coukos, G., & Muzykantov, V. R. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.808184 · Cited by 106
Heyn, H., Morán, S., & Esteller, M. (2012) · Epigenetics · doi:10.4161/epi.23366 · Cited by 105
Wen, P. Y., Cloughesy, T. F., Olivero, A. G., Morrissey, K. M., Wilson, T. R., Lu, X., Mueller, L. U., Coimbra, A. F., Ellingson, B. M., Gerstner, E. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2808 · Cited by 104
Joel, M., Mughal, A. A., Grieg, Z., Murrell, W. G., Palmero, S., Mikkelsen, B., Fjerdingstad, H. B., Sandberg, C. J., Behnan, J., Glover, J. C., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0398-x · Cited by 102
Manfredini, S., Pavan, B., Vertuani, S., Scaglianti, M., Compagnone, D., Biondi, C., Scatturin, A., Tanganelli, S., Ferraro, L., Prasad, P. D., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015556r · Cited by 102
Mai, W. X., Gosa, L., Daniëls, V. W., Ta, L. H., Tsang, J., Higgins, B., Gilmore, W. B., Bayley, N. A., Harati, M. D., Lee, J. T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4418 · Cited by 100
Integrating cancer genomics and proteomics in the post-genome era
Hanash, S., Bobek, M. P., Rickman, D. S., Williams, T., Rouillard, J. M., Kuick, R. D., & Puravs, E. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200201)2:1<69::aid-prot69>3.0.co;2-8 · Cited by 98
FDC-SP, a Novel Secreted Protein Expressed by Follicular Dendritic Cells
Marshall, A. J., Du, Q., Draves, K. E., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2381 · Cited by 93
A Novel NF-κB Binding Site Controls Human Granzyme B Gene Transcription
Huang, C., Bi, E., Hu, Y., Deng, W., Tian, Z., Dong, C., Hu, Y., & Sun, B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.4173 · Cited by 92
Gomes, P., & Soares-da-Silva, P. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01387-6 · Cited by 92
Jiang, Y., Wang, X., Liu, X., Lv, W., Zhang, H., Zhang, M., Li, X., Xin, H., & Xu, Q. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b13805 · Cited by 91
Polisetty, R. V., Gautam, P., Sharma, R., Gowda, H., Nair, S. C., Gupta, M. K., Uppin, M. S., Challa, S., Puligopu, A. K., Ankathi, P., et al. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.013565 · Cited by 86
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Kalpathy–Cramer, J., Chandra, V., Da, X., Ou, Y., Emblem, K. E., Muzikansky, A., Cai, X., Douw, L., Evans, J. G., Dietrich, J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2332-5 · Cited by 84
Expression and localization of VEGF‐C and VEGFR‐3 in glioblastomas and haemangioblastomas
Jenny, B., Harrison, J., Baetens, D., Tille, J., Burkhardt, K., Mottaz, H., Kiss, J., Dietrich, P., de Tribolet, N., Pizzolato, G., et al. (2006) · The Journal of Pathology · doi:10.1002/path.1943 · Cited by 83
Development of Proteomic Patterns for Detecting Lung Cancer
Xiao, X., Liu, D., Tang, Y., Guo, F., Xia, L., Liu, J., & He, D. (2003) · Disease Markers · doi:10.1155/2003/278152 · Cited by 82
EGFR tyrosine kinase domain mutations in human gliomas
Marie, Y., Carpentier, A. F., Omuro, A. M. P., Sanson, M., Thillet, J., Hoang‐Xuan, K., & Delattre, J. (2005) · Neurology · doi:10.1212/01.wnl.0000158654.07080.b0 · Cited by 79
Prizment, A. E., Vierkant, R. A., Smyrk, T. C., Tillmans, L. S., Nelson, H. H., Lynch, C. F., Pengo, T., Thibodeau, S. N., Church, T. R., Cerhan, J. R., et al. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0641 · Cited by 78
Yamashita, Y., Nishiumi, S., Kono, S., Takao, S., Azuma, T., & Yoshida, M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3554-4 · Cited by 77
Soltys, S. G., Le, Q., Shi, G., Tibshirani, R. J., Giaccia, A. J., & Koong, A. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0469 · Cited by 75
Roles of Metalloproteases in Metastatic Niche
Rucci, N., Sanità, P., & Angelucci, A. (2011) · Current Molecular Medicine · doi:10.2174/156652411797536705 · Cited by 75
AP‐2α and AP‐2γ regulate tumor progression via specific genetic programs
Orso, F., Penna, E., Cimino, D., Astanina, E., Maione, F., Valdembri, D., Giraudo, E., Serini, G., Sismondi, P., Bortoli, M. D., et al. (2008) · The FASEB Journal · doi:10.1096/fj.08-106492 · Cited by 74
Network Signatures of Survival in Glioblastoma Multiforme
Patel, V. N., Gokulrangan, G., Chowdhury, S. A., Chen, Y., Sloan, A. E., Koyutürk, M., Barnholtz‐Sloan, J. S., & Chance, M. R. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003237 · Cited by 73
Fernández, C. I., Nieto, O., Fontenla, J. A., Rivas, E., CEBALLOS, M. L. D., & Fernández‐Mayoralas, A. (2003) · Organic & Biomolecular Chemistry · doi:10.1039/b212066f · Cited by 73
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma
Sareddy, G. R., Li, X., Liu, J., Viswanadhapalli, S., Garcia, L., Gruslova, A., Cavazos, D., Garcia, M., Ström, A., Gustafsson, J.-Α., et al. (2016) · Scientific Reports · doi:10.1038/srep24185 · Cited by 71
Mercapide, J., de Cicco, R. L., Bassi, D., Castresana, J. S., Thomas, G., & Klein–Szanto, A. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0489 · Cited by 70
Down-regulation of Human Granzyme B Expression by Glucocorticoids
Wargnier, A., Lafaurie, C., Legros-Maïda, S., Bourge, J., Sigaux, F., Sasportes, M., & Paul, P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.52.35326 · Cited by 69
Katchman, B. A., Antwi, K., Hostetter, G. H., Demeure, M. J., Watanabe, A. T., Decker, G. A., Miller, L. J., Hoff, D. D. V., & Lake, D. F. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0018 · Cited by 69
Sunaga, N., Kaira, K., Imai, H., Shimizu, K., 中野, 哲., Shames, D. S., Girard, L., Soh, J., Sato, M., Iwasaki, Y., et al. (2012) · Oncogene · doi:10.1038/onc.2012.402 · Cited by 68
Marien, E., Meister, M. A., Muley, T., del Pulgar, T. G., Derua, R., Spraggins, J. M., de Plas, R. V., Vanderhoydonc, F., Machiels, J., Binda, M. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7179 · Cited by 68
A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers
Siefker-Radtke, A. O., Zhang, X.-Q., Guo, C. C., Shen, Y., Pirollo, K. F., Sabir, S. H., Leung, C., Leong-Wu, C. A., Ling, C.-M., Chang, E. H., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.118 · Cited by 66
Zou, J., Guo, P., Lv, N., & Huang, D. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4243 · Cited by 65
Ho, D. W., Kai, A. K., & Ng, I. O. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0408-9 · Cited by 64
Elovl6 is a poor prognostic predictor in breast cancer
FENG, Y.-H., CHEN, W.-Y., Kuo, Y.-H., Tung, C., Tsao, C., Shiau, A., & Wu, C. (2016) · Oncology Letters · doi:10.3892/ol.2016.4587 · Cited by 64
Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences
Tosoni, A., Franceschi, E., Poggi, R., & Brandes, A. A. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0422-4 · Cited by 64
Ghiaseddin, A. P., Reardon, D. A., Massey, W. C., Mannerino, A., Lipp, E., Herndon, J. E., McSherry, F., Desjardins, A., Randazzo, D. M., Friedman, H. S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0501 · Cited by 63
NF1 loss disrupts Schwann cell–axonal interactions: a novel role for semaphorin 4FPreprint
Parrinello, S., Noon, L. A., Harrisingh, M. C., Wingfield-Digby, P., Rosenberg, L. H., Cremona, C. A., Echave, P., Flanagan, A. M., Parada, L. F., & Lloyd, A. C. (2008) · Genes & Development · doi:10.1101/gad.490608 · Cited by 62
A Cell-Surface Membrane Protein Signature for Glioblastoma
Ghosh, D., Funk, C. C., Caballero, J., Shah, N., Rouleau, K., Earls, J. C., Soroceanu, L., Foltz, G., Cobbs, C., Price, N. D., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2017.03.004 · Cited by 62
Simeonova, I., & Huillard, E. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1675-3 · Cited by 61
Hanavan, P. D., Borges, C. R., Katchman, B. A., Faigel, D. O., Ho, T. H., Ma, C.-T., Sergienko, E. A., Meurice, N., Petit, J. L., & Lake, D. F. (2015) · Oncotarget · doi:10.18632/oncotarget.4099 · Cited by 59
Lorenzi, L., Döring, C., Rausch, T., Beneš, V., Lonardi, S., Bugatti, M., Campo, E., Cabeçadas, J., Simonitsch‐Klupp, I., Borges, A. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14864 · Cited by 59
Dreyfuss, J. M., Johnson, M. D., & Park, P. J. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-71 · Cited by 58
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma
Clarke, J. L., Molinaro, A. M., Cabrera, J. R., DeSilva, A. A., Rabbitt, J. E., Prey, J. D., Drummond, D. C., Kim, J., Noble, C. O., Fitzgerald, J. B., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3247-3 · Cited by 58
Shimizu‐Hirota, R., Sasamura, H., Kuroda, M., Kobayashi, E., & Saruta, T. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00250-9 · Cited by 55
Jiang, X., Zhou, T., Wang, Z., Qi, B., & Xia, H. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00253 · Cited by 54
Seol, M.-A., Chu, I., Lee, M.-J., Yu, G., Cui, X.-D., Cho, B., Ahn, E.-K., Leem, S., Kim, I., & Kim, D. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-78 · Cited by 53
Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles
Bauerschlag, D., Ammerpohl, O., Bräutigam, K., Schem, C., Lin, Q., Weigel, M. T., Hilpert, F., Arnold, N., Maass, N., Meinhold-Heerlein, I. M., et al. (2011) · Oncology · doi:10.1159/000327746 · Cited by 52
Grinshtein, N., Rioseco, C. C., Marcellus, R. C., Uehling, D., Aman, A. M., Lun, X. Q., Muto, O., Podmore, L., Lever, J., Shen, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10661 · Cited by 52
van den Bent, M. J., Azaro, A., Vos, F. D., Sepúlveda-Sánchez, J. M., Yung, W. K. A., Wen, P. Y., Lassman, A. B., Joerger, M., Tabatabai, G., Rodon, J. A., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03337-2 · Cited by 52
Zhou, Y., Shan, S., Li, Z., Xin, L., Pan, D., Yang, Q., Liu, Y., Yue, X., Liu, X., Gao, J., et al. (2016) · Cancer Science · doi:10.1111/cas.13141 · Cited by 49
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma
Fathi, A. T., Nahed, B. V., Wander, S. A., Iafrate, A. J., Borger, D. R., Hu, R., Thabet, A., Cahill, D. P., Perry, A. M., Joseph, C. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0342 · Cited by 47
Woodham, A. W., Taylor, J. R., Jimenez, A. I., Skeate, J. G., Schmidt, T. H., Brand, H. E., Silva, D. M. D., & Kast, W. M. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv045 · Cited by 45
Martorell, Ò., Barriga, F. M., Merlos‐Suárez, A., Attolini, C. S., Casanova, J., Batlle, E., Sancho, E., & Casali, A. (2014) · EMBO Reports · doi:10.15252/embr.201438622 · Cited by 44
Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies
William, D., Mullins, C. S., Schneider, B., Orthmann, A., Lamp, N., Krohn, M., Hoffmann, A., Classen, C.-F., & Linnebacher, M. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1128-5 · Cited by 43
Insulin Fragments as a Carrier for Peptide Delivery Across the Blood–Brain Barrier
Fukuta, M., Okada, H., IINUMA, S., Yanai, S., & Toguchi, H. (1994) · Pharmaceutical Research · doi:10.1023/a:1018942728317 · Cited by 41
Synthetic lethality-based targets for discovery of new cancer therapeutics.
Weidle, U. H., Maisel, D., & Eick, D. (2011) · PubMed · Cited by 41
Reddy, T. R. K., Li, C., Fischer, P. M., & Dekker, L. V. (2012) · ChemMedChem · doi:10.1002/cmdc.201200107 · Cited by 40
Kim, Y.-W., Liu, T. J., Koul, D., Tiao, N., Feroze, A. H., Wang, J., Powis, G., & Yung, W. K. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor012 · Cited by 39
Structural Studies Revealed Active Site Distortions of Human Furin by a Small Molecule Inhibitor
Dahms, S. O., Jiao, G., & Than, M. E. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01110 · Cited by 39
Cited by
Artificial intelligence for multimodal data integration in oncology
Lipkova, J., Chen, R. J., Chen, B., Lu, M. Y., Barbieri, M., Shao, D., Vaidya, A. J., Chen, C., Zhuang, L., Williamson, D. F. K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.012 · Cited by 777
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G., & Hatley, R. J. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 540
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Nanocarrier-based drug combination therapy for glioblastoma
Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M. (2020) · Theranostics · doi:10.7150/thno.38147 · Cited by 373
Metadata
- Authors
- Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 70
- Issue
- 3
- Pages
- 412-445
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2800469107
- Cited by
- 849
- References
- 238
- FWCI
- 38.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.